Direct and Indirect Pathways for Health-Related Quality of Life Change from Pain Improvement in Neuropathic Pain Patients with Spine Diseases: Path Analysis with Structural Equation Modeling Using Non-Interventional Study Results of Pregabalin.

EuroQoL 5 Dimensions function neuropathic pain pregabalin spine diseases structural equation modeling

Journal

Journal of pain research
ISSN: 1178-7090
Titre abrégé: J Pain Res
Pays: New Zealand
ID NLM: 101540514

Informations de publication

Date de publication:
2021
Historique:
received: 29 10 2020
accepted: 28 04 2021
entrez: 9 6 2021
pubmed: 10 6 2021
medline: 10 6 2021
Statut: epublish

Résumé

Chronic low back pain or chronic cervical pain often has a neuropathic pain (NeP) component and patients with these conditions complain of sleep deprivation, loss of physical function, and reduced productivity due to pain. The objective of this study was to clarify the pathway by which pain, sleep disturbance due to pain, and physical function status influence QOL measures in chronic low back pain patients with NeP associated with lumbar spine diseases (CLBP-NeP) and in chronic cervical pain patients with NeP associated with cervical spine diseases (CCP-NeP). A model assuming pain numeric rating scale (NRS), pain-related sleep interference scale (PRSIS), and functional indices (Roland Morris Disability Questionnaire [RMDQ], Neck Disability index [NDI]) as factors that can affect outcomes such as QOL (calculated using EuroQoL 5 Dimensions (EQ-5D)), the Patient Global Impression of Change (PGIC), and the Clinical Global Impression of Change (CGIC) was developed using structural equation modeling. Overall trends were frequently observed in both patients with CLBP-NeP and CCP-NeP. Pain NRS had the largest comprehensive direct impact on QOL based on EQ-5D and an overall impression of changing symptoms. The effects of pain NRS on each outcome were largely due to direct pain-related effects; however, for EQ-5D, an indirect effect via functional improvement was the primary factor. Although the results of this study suggest that the indirect functional improvement of pain relief may not be recognized as a significant component of therapeutic effects by both physicians and patients, the pain-relieving intervention contributes directly to improvement of patients' overall QOL and also indirectly via functional improvement in Japanese primary care settings. Accordingly, to achieve the therapeutic goal for patients with NeP and minimize the impact of pain burden, our findings indicate that pain relief interventions are also crucial from the perspective of the patient's HRQOL.

Sections du résumé

BACKGROUND BACKGROUND
Chronic low back pain or chronic cervical pain often has a neuropathic pain (NeP) component and patients with these conditions complain of sleep deprivation, loss of physical function, and reduced productivity due to pain. The objective of this study was to clarify the pathway by which pain, sleep disturbance due to pain, and physical function status influence QOL measures in chronic low back pain patients with NeP associated with lumbar spine diseases (CLBP-NeP) and in chronic cervical pain patients with NeP associated with cervical spine diseases (CCP-NeP).
METHODS METHODS
A model assuming pain numeric rating scale (NRS), pain-related sleep interference scale (PRSIS), and functional indices (Roland Morris Disability Questionnaire [RMDQ], Neck Disability index [NDI]) as factors that can affect outcomes such as QOL (calculated using EuroQoL 5 Dimensions (EQ-5D)), the Patient Global Impression of Change (PGIC), and the Clinical Global Impression of Change (CGIC) was developed using structural equation modeling.
RESULTS RESULTS
Overall trends were frequently observed in both patients with CLBP-NeP and CCP-NeP. Pain NRS had the largest comprehensive direct impact on QOL based on EQ-5D and an overall impression of changing symptoms. The effects of pain NRS on each outcome were largely due to direct pain-related effects; however, for EQ-5D, an indirect effect via functional improvement was the primary factor.
CONCLUSION CONCLUSIONS
Although the results of this study suggest that the indirect functional improvement of pain relief may not be recognized as a significant component of therapeutic effects by both physicians and patients, the pain-relieving intervention contributes directly to improvement of patients' overall QOL and also indirectly via functional improvement in Japanese primary care settings. Accordingly, to achieve the therapeutic goal for patients with NeP and minimize the impact of pain burden, our findings indicate that pain relief interventions are also crucial from the perspective of the patient's HRQOL.

Identifiants

pubmed: 34103979
doi: 10.2147/JPR.S289396
pii: 289396
pmc: PMC8179792
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1543-1551

Informations de copyright

© 2021 Taguchi et al.

Déclaration de conflit d'intérêts

This study was sponsored by Pfizer Japan Inc. Kazutaka Nozawa and Koichi Fujii are employees of Pfizer Japan Inc. Shigeki Zeniya and Tatsunori Murata are employees of CRECON Medical Assessment Inc. Thomas Laurent and Takahiro Hirano are employees of Clinical Study Support, Inc. Toshihiko Taguchi was not financially compensated for their collaboration in this project or for the development of this manuscript, although Toshihiko Taguchi has received honorarium from Pfizer Japan Inc. outside of this work. The authors report no other conflicts of interest in this work.

Références

Psychol Bull. 1990 Mar;107(2):238-46
pubmed: 2320703
Environ Health Prev Med. 2008 Mar;13(2):109-15
pubmed: 19568889
Spine (Phila Pa 1976). 2008 Jan 1;33(1):95-103
pubmed: 18165754
Spine (Phila Pa 1976). 2010 Aug 15;35(18):1714-20
pubmed: 21374895
Patient. 2014;7(1):107-14
pubmed: 24263740
Clin J Pain. 2013 Oct;29(10):846-56
pubmed: 23364214
PLoS One. 2015 Jun 15;10(6):e0129262
pubmed: 26076135
J Pain Res. 2015 Feb 25;8:119-30
pubmed: 25750546
Spine (Phila Pa 1976). 2008 Feb 15;33(4 Suppl):S192-8
pubmed: 18204392
J Pain Res. 2019 May 03;12:1411-1424
pubmed: 31118759
Pain. 2001 Sep;93(3):317-325
pubmed: 11514090
Spine (Phila Pa 1976). 2003 Jun 1;28(11):1195-202
pubmed: 12782992
J Orthop Sci. 2015 Mar;20(2):403-9
pubmed: 25432527
J Pain Res. 2015 Aug 05;8:487-97
pubmed: 26346468
J Orthop Sci. 2013 Mar;18(2):216-9
pubmed: 23232803
J Orthop Sci. 2014 Jan;19(1):15-21
pubmed: 24306580

Auteurs

Toshihiko Taguchi (T)

Japan Organization of Occupational Health and Safety, Yamaguchi Rosai Hospital, Sanyo-Onoda, Yamaguchi, Japan.

Kazutaka Nozawa (K)

Medical Affairs, Pfizer Japan Inc, Tokyo, Japan.

Shigeki Zeniya (S)

CRECON Medical Assessment Inc., Tokyo, Japan.

Tatsunori Murata (T)

CRECON Medical Assessment Inc., Tokyo, Japan.

Thomas Laurent (T)

Clinical Study Support, Inc, Nagoya, Japan.

Takahiro Hirano (T)

Clinical Study Support, Inc, Nagoya, Japan.

Koichi Fujii (K)

Medical Affairs, Pfizer Japan Inc, Tokyo, Japan.

Classifications MeSH